Clinical Trial Update: Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet [Phase 2]

View source ↗

Summary

A Phase IIb one-year study evaluating the efficacy and safety of S-2367 in obese subjects on a reduced-calorie diet has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• S-2367

Snippet

Sponsor: Shionogi | Conditions: Obesity | Phase 2 | Status: COMPLETED